Back to Trials
NCT06269510NARecruiting

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

Henry Ford Health System

Start Date

1/28/2026

Completion Date

2/1/2030

Summary

The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

Detailed Description

Eligible participants will be randomized to stage 1 of treatment which consists of a previously pilot-tested behavioral application (app), the ENGAGE-ALD app, consisting of a knowledge improvement module and a preference-sensitive treatment matching module. Those who do not engage in AUD treatment after randomization ('non-responders') will be re-randomized at 3-months and continue on this in stage two if considered a responder (met treatment engagement). Participants that were not considered to have met "treatment engagement" will be re-randomized at 3-months to a Treatment Facilitation bundle consisting of a barriers to treatment survey followed by a health coaching session.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Willingness to comply with all study procedures and availability for the duration of the study * Willing and able to provide informed consent * Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals * Documented diagnosis of alcohol-related liver disease (ALD) (per protocol) * Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record. * No alcohol use treatment within the past 1 month including, but not limited to: * Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use. * Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery) * Community-based church support groups primarily focused on alcohol abstinence or reduction in use. * Residential (inpatient) alcohol treatment * Intensive outpatient programs * Any telehealth version of the above options * Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling/data plan at no cost to subject by the study team for the duration of the research stud. * Ability to speak and comprehend English Exclusion Criteria: * Unable to provide voluntary informed consent for any reason * Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score \>=10 on the Short Blessed Test for cognitive impairment. * Unable to read or understand English * Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation * Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine * Any other medical condition or circumstance that precludes safe and meaningful participation in the study * History of nonadherence to previous clinical or research studies

Interventions

BEHAVIORAL

ENGAGE-ALD Application (APP)

BEHAVIORAL

Treatment Facilitation bundle

BEHAVIORAL

Enhanced Usual Care

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Alcohol-related Liver DiseaseLiver Diseases

Locations

Henry Ford Health

Detroit, Michigan 48202

United States